MTOR and B-cell chronic lymphocytic leukemia: Plasma MV from CLL patients seem to activate the AKT/mTOR pathway in BM-MSC from CLL patients and elicit VEGF and hypoxia-inducible factor 1 (HIF-1) production, which thereby increase the proangiogenic potential.